Bryostatin-1 for Recurrent Ovarian Cancer
Author Information
Author(s): Clamp A R, Blackhall F H, Vasey P, Soukop M, Coleman R, Halbert G, Robson L, Jayson G C
Primary Institution: Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust
Hypothesis
Can bryostatin-1 be effective in treating recurrent epithelial ovarian carcinoma?
Conclusion
The study found that bryostatin-1 did not show significant efficacy in managing relapsed chemotherapy-resistant epithelial ovarian cancer.
Supporting Evidence
- Bryostatin-1 was administered weekly at a dose of 25 μg m−2 for a planned eight doses.
- No radiological or CA-125 responses were noted on therapy.
- Six patients had early disease progression prior to the planned assessment after eight doses of bryostatin-1.
Takeaway
Doctors tested a new drug called bryostatin-1 on women with a type of cancer that came back after treatment, but it didn't help them get better.
Methodology
This was a multicentre open label nonrandomised Phase II trial focusing on response rate and progression-free interval.
Potential Biases
The study was nonrandomised, which may introduce bias in treatment effects.
Limitations
The study primarily involved patients with chemotherapy-resistant disease, which is known to have low response rates to new treatments.
Participant Demographics
The median age of participants was 60 years, with a range from 43 to 71; all had undergone surgery and platinum-based chemotherapy.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website